Table 1.

Baseline Characteristics of Patients

Characteristic	Mild or No RI: CLCr ≥60 mL/min	Moderate RI: CLCr ≥30 mL/min to <60 mL/min	Severe RI: CLCr <30 mL/min
No. of patients	243	82	16
Median age (range), y	61 (33-82)	69 (38-84)a	73 (56-86)a
Men, %	67	43a	25a
ECOG score 0 or 1, %	89	87	69
Median time since diagnosis (range), y	3.1 (0.4-15.7)	3.4 (0.5-14.6)	3.4 (1.0-8.7)
Bone lesions, %	75	72	69
Serum β2-microglubulin >2.5 mg/L, %	62	89a	100a
Immunoglobulin G, %	66	63	56
Immunoglobulin A, %	21	20	19
Durie-Salmon stage III, %	62	72	75
No. of prior lines of therapy, median (range)	2 (0-8)	2 (0-5)	2 (0-3)
Prior therapies, %
Thalidomide	35	33	56
Bortezomib	9	6	0

RI indicates renal impairment; CL_Cr, creatinine clearance; ECOG, Eastern Cooperative Oncology Group.

^aP < .05 versus patients with mild or no RI.